Eribulin mesylate is a synthetic macrocyclic
ketone analog of the marine sponge
natural product halichondrin B and an inhibitor of microtubule dynamics. Some
tubulin-binding drugs are known to have antivascular (antiangiogenesis or vascular-disrupting) activities that can target abnormal
tumor vessels. Using dynamic contrast-enhanced MRI analyses, here we show that
eribulin induces remodeling of
tumor vasculature through a novel antivascular activity in MX-1 and MDA-MB-231 human
breast cancer xenograft models.
Vascular remodeling associated with improved perfusion was shown by
Hoechst 33342 staining and by increased microvessel density together with decreased mean vascular areas and fewer branched vessels in
tumor tissues, as determined by immunohistochemical staining for endothelial marker CD31. Quantitative RT-PCR analysis of normal host cells in the stroma of xenograft
tumors showed that
eribulin altered the expression of mouse (host) genes in angiogenesis signaling pathways controlling endothelial cell-pericyte interactions, and in the epithelial-mesenchymal transition pathway in the context of the tumor microenvironment.
Eribulin also decreased
hypoxia-associated
protein expression of mouse (host)
vascular endothelial growth factor by ELISA and human CA9 by immunohistochemical analysis. Prior treatment with
eribulin enhanced the anti-
tumor activity of
capecitabine in the MDA-MB-231 xenograft model. These findings suggest that
eribulin-induced remodeling of abnormal
tumor vasculature leads to a more functional microenvironment that may reduce the aggressiveness of
tumors due to elimination of inner tumor hypoxia. Because abnormal tumor microenvironments enhance both drug resistance and
metastasis, the apparent ability of
eribulin to reverse these aggressive characteristics may contribute to its clinical benefits.